Clinical Trial

A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The primary objective is to evaluate the safety and tolerability of RC278; determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of RC278; and determine the recommended phase 2 dose (RP2D)， and assess the efficacy of RC278 at the RP2D dose;
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-29; most recent amendment 2025-11-24.
Status change: Not Yet Recruiting → Recruiting 2025-08-13
Trial Details
NCT Number NCT07105215
Lead Sponsor RemeGen Co., Ltd.
Conditions Solid Tumors
Enrollment 312 participants
Start Date 2025-08-11
Primary Completion 2027-12-31 (estimated)
Study Completion 2030-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-26